Allopurinol and Cardiovascular Outcomes in Adults with Hypertension

Hypertension

Volumn 67, Issue 3, 2016, Pages 535-540

  MacIsaac, Rachael L ^a   Salatzki, Janek ^a   Higgins, Peter ^a   Walters, Matthew R ^a   Padmanabhan, Sandosh ^a   Dominiczak, Anna F ^a   Touyz, Rhian M ^a   Dawson, Jesse ^b  

^a QUEEN ELIZABETH UNIVERSITY HOSPITAL   (United Kingdom)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

allopurinol; blood pressure; hypertension; prevention control; stroke

Indexed keywords

ALLOPURINOL; ANTIMETABOLITE;

ADULT; AGED; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EXPOSURE; DRUG MEGADOSE; FOLLOW UP; HEART PROTECTION; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICAL HISTORY; OUTCOME ASSESSMENT; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY HEALTH CARE; ADOLESCENT; BLOOD PRESSURE; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; FEMALE; GREAT BRITAIN; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; RISK FACTOR; STROKE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLOPURINOL; ANTIMETABOLITES; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; HYPERTENSION; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; STROKE; YOUNG ADULT;

EID: 84958043634     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.115.06344     Document Type: Article

References (32)

1. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension. 2001; 38: 1101-1106.
2. Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011; 63: 102-110. doi: 10.1002/acr.20344.
3. Dawson J, Walters M. Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol. 2006; 62: 633-644.
4. Borghi, C; Rosei, A. Bardin, T. Dawson, J. Dominiczak, A. Kielstein, J T. Manolis, A J. Perez-Ruiz, F. Mancia, G. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertension 2015; 33: 1729-1741.
5. Agarwal A, Banerjee A, Banerjee UC. Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling. Crit Rev Biotechnol. 2011; 31: 264-280.
6. Soletsky B, Feig DI. Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension. 2012; 60: 1148-1156. doi: 10.1161/HYPERTENSIONAHA.112.196980.
7. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA. 2008; 300: 924-932. doi: 10.1001/jama.300.8.924.
8. Agarwal V, Hans N, Messerli FH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013; 15: 435-442. doi: 10.1111/j.1751-7176.2012.00701.x.
9. Beattie CJ, Fulton RL, Higgins P, Padmanabhan S, McCallum L, Walters MR, Dominiczak AF, Touyz RM, Dawson J. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension. 2014; 64: 1102-1107. doi: 10.1161/HYPERTENSIONAHA.114.03953.
10. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006; 114: 2508-2516. doi: 10.1161/CIRCULATIONAHA.106.651117.
11. Kao MP, Ang DS, Gandy SJ, Nadir MA, Houston JG, Lang CC, Struthers AD. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 1382-1389. doi: 10.1681/ASN.2010111185.
12. Dubreuil M, Zhu Y, Zhang Y, Seeger JD, Lu N, Rho YH, Choi HK. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis. 2015; 74: 1368-1372. doi: 10.1136/annrheumdis-2014-205269.
13. Kok VC, Horng JT, Chang WS, Hong YF, Chang TH. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: a population-based matched-cohort study. PLoS One. 2014; 9: e99102. doi: 10.1371/journal.pone.0099102.
14. Walley T, Mantgani A. The UK General Practice Research Database. Lancet. 1997; 350: 1097-1099. doi: 10.1016/S0140-6736(97)04248-7.
15. Lawson DH, Sherman V, Hollowell J. The General Practice Research Database. Scientific and Ethical Advisory Group. QJM. 1998; 91: 445-452.
16. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991; 302: 766-768.
17. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol. 2002; 282: F991-F997. doi: 10.1152/ajprenal.00283.2001.
18. Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA. 1993; 270: 354-359.
19. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, Fisher ND. Uric acid and the state of the intrarenal renin-angiotensin system in humans. Kidney Int. 2004; 66: 1465-1470. doi: 10.1111/j.1523-1755.2004.00909.x.
20. Lanadmesser U, Spiekermann S, Preuss C, Sorrentino S, Fischer D, Manes C, Mueller M, Drexler H. Angiotensin II induces endothelial xanthine oxidase activation: role for endothelial dysfunction in patients with coronary disease. Arterioscler Thromb Vasc Biol. 2007; 27: 943-948. doi: 10.1161/01.ATV.0000258415.32883.bf.
21. Higgins P, Walters MR, Murray HM, McArthur K, McConnachie A, Lees KR, Dawson J. Allopurinol reduces brachial and central blood pressure, and carotid intima-media thickness progression after ischaemic stroke and transient ischaemic attack: a randomised controlled trial. Heart. 2014; 100: 1085-1092. doi: 10.1136/heartjnl-2014-305683.
22. Szwejkowski BR, Gandy SJ, Rekhraj S, Houston JG, Lang CC, Morris AD, George J, Struthers AD. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol. 2013; 62: 2284-2293. doi: 10.1016/j.jacc.2013.07.074.
23. Rekhraj S, Gandy SJ, Szwejkowski BR, Nadir MA, Noman A, Houston JG, Lang CC, George J, Struthers AD. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol. 2013; 61: 926-932. doi: 10.1016/j.jacc.2012.09.066.
24. Noman A, Ang DS, Ogston S, Lang CC, Struthers AD. Effect of highdose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet. 2010; 375: 2161-2167. doi: 10.1016/S0140-6736(10)60391-1.
25. Higgins P, Dawson J, Lees KR, McArthur K, Quinn TJ, Walters MR. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012; 30: 217-226. doi: 10.1111/j.1755-5922.2011.00277.x.
26. Struthers AD, Donnan PT, Lindsay P, McNaughton D, Broomhall J, MacDonald TM. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart. 2002; 87: 229-234.
27. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis. 1981; 40: 245-249.
28. Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi HK. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford). 2009; 48: 804-806. doi: 10.1093/rheumatology/kep069.
29. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010; 170: 1358-1364. doi: 10.1001/archinternmed.2010.198.
30. Wu AH, Ghali JK, Neuberg GW, O'Connor CM, Carson PE, Levy WC. Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J. 2010; 160: 928-933. doi: 10.1016/j.ahj.2010.08.006.
31. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP; OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008; 51: 2301-2309. doi: 10.1016/j.jacc.2008.01.068.
32. Grodzicki T, Palmer A, Bulpitt CJ. Incidence of diabetes and gout in hypertensive patients during 8 years of follow-up. The General Practice Hypertension Study Group. J Hum Hypertens. 1996; 11: 583-585.